CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
SUBLICENSE REVENUE	$ 0	$ 0
OPERATING EXPENSES:
Sublicense transaction costs	0	0
General and administrative	188	229
Research and development	601	301
Total operating expenses	789	530
Income (loss) after operating expenses	(789)	(530)
Interest and other income (expense), net	(63)	(60)
Income (loss) from operations before taxes	(852)	(590)
Income tax benefit (expense)	(3)	3
NET INCOME (LOSS)	(855)	(587)
Less: Net Income (Loss) attributable to the noncontrolling interest	0	0
Net Income (Loss) attributable to Capstone Therapeutics Corp. stockholders	$ (855)	$ (587)
Per Share Information:
Net Income (Loss), basic and diluted, attributable to Capstone Therapeutic Corp. stockholders	$ (0.02)	$ (0.01)
Basic and diluted shares outstanding	54,385	54,385